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treatment
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Abstract
Background: The pathophysiology, including the impact of gene expression, of polymyalgia rheumatica (PMR)
remains elusive. We profiled the gene expression in muscle tissue in PMR patients before and after glucocorticoid
treatment.
Methods: Gene expression was measured using Affymetrix Human Genome U133 Plus 2.0 arrays in muscle biopsies
from 8 glucocorticoid-naive patients with PMR and 10 controls before and after prednisolone-treatment for 14 days.
For 14 genes, quantitative real-time PCR (qRT-PCR, n = 9 in both groups) was used to validate the microarray findings
and to further investigate the expression of genes of particular interest.
Results: Prednisolone normalized erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) in PMR patients. A
total of 165 putatively clinically relevant, differentially expressed genes were identified (cut-off: fold difference > ±1.2,
difference of mean > 30, and p < 0.05); of these, 78 genes differed between patients and controls before treatment,
131 genes responded to treatment in a given direction only in patients, and 44 fulfilled both these criteria. In 43 of the
44 genes, treatment counteracted the initial difference. Functional clustering identified themes of biological function,
including regulation of protein biosynthesis, and regulation of transcription and of extracellular matrix processes.
Overall, qRT-PCR confirmed the microarray findings: Microarray-detected group differences were confirmed for 9 genes
in 17 of 18 comparisons (same magnitude and direction of change); lack of group differences in microarray testing was
confirmed for 5 genes in 8 of 10 comparisons. Before treatment, using qRT-PCR, expression of interleukin 6 (IL-6) was
found to be 4-fold higher in patients (p < 0.05).
Conclusions: This study identifies genes in muscle, the expression of which may impact the pathophysiology of PMR.
Moreover, the study adds further evidence of the importance of IL-6 in the disease. Follow-up studies are needed to
establish the exact pathophysiological relevance of the identified genes.
The study was retrospectively listed on the ISRCTN registry with study ID ISRCTN69503018 and date of registration the
26th of July 2017.
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Background
Polymyalgia rheumatica (PMR) affects men and women
above the age of 50 and is recognized as the most com-
mon chronic inflammatory, rheumatic disease in this age
group [1–3]. Clinically, PMR is associated with promin-
ent muscle complaints, including aching and tender and
stiff proximal muscles [1]. Paraclinically, erythrocyte sedi-
mentation rate (ESR) and blood levels of C-reactive protein
(CRP) are markedly elevated [1]. Furthermore, concentra-
tions of proinflammatory cytokines, including also interleu-
kin (IL) 6 [4, 5], are elevated systemically as well as locally
in muscle tissue [5]. Yet, the prevailing view is that PMR
reflects inflammation in the synovia of bursae, joints and
tendon sheaths [6]. Overall, however, the current under-
standing of the etiology, pathogenesis and pathophysiology
of PMR is modest. Treatment with glucocorticoids (GCs)
is rapidly effective [7, 8], and the majority of patients main-
tains remission, but many experience at least one GC-
related serious adverse event [9].
The genetics of PMR remain elusive; however, the
higher incidence in Caucasians [10] and the higher sus-
ceptibility in people carrying the HLA-DRB1*04 allele
[11] suggest that genetic factors may in fact impact the
pathophysiology of the disease. Studies have found asso-
ciations between polymorphisms in the genes encoding
e.g. IL-6 and tumor necrosis factor alpha (TNF-α) and
the susceptibility to and severity of PMR [12], but gener-
ally findings have been inconclusive [13, 14].
In the present study, to extend the understanding of the
pathophysiology of PMR, we profiled the gene expression
in muscle tissue from GC-naive patients with PMR and
matched non-PMR control subjects before and after
symptom-eliminating treatment with prednisolone.
Methods
Subjects
Nine GC-naive patients with newly diagnosed, untreated
PMR and 10 matched (age, sex, and BMI) non-PMR
control subjects were studied in the fasting state in the
morning before and after 14 days of prednisolone treat-
ment (20 mg/day taken in the morning, also 1–2 h
before the second biopsy) in a comprehensive clinical
experimental research program, some of the results of
which we recently reported [5, 15]. The study was ap-
proved by the Ethical Committee of Copenhagen (ap-
proval number: KF[01]261665) and informed consent
was obtained before study inclusion. Anthropometric
data are given in Table 1.
Patients were diagnosed with PMR according to the cri-
teria proposed by Chuang and colleagues [2, 3, 16, 17], and
the diagnosis was later supported by normalization of ESR
and CRP upon prednisolone treatment. Patients were re-
cruited by referral from general practitioners; control sub-
jects were recruited by newspaper advertising and included
in the study after a standard medical examination and a
comprehensive blood and urine screening. Both groups did
not meet the exclusion criteria described by Kreiner and
colleagues [5]. Controlled chronic comorbidities were ac-
cepted in both groups. Diminishing the possibility of occult
malignant disease, all subjects had normal thorax X-ray
and abdominal ultrasound examination, and negative test
for blood in the stools and urine. In addition, all subjects
had comprehensive blood screening performed. In pa-
tients, only ESR and CRP were different from normal
values; no blood values in control subjects were abnormal.
Some subjects received concurrent medication as pre-
viously detailed [5]. Before the first experiment, non-
steroidal anti-inflammatory drug treatment was not
allowed, and use of analgesics was limited to the
centrally-acting opioid-like drug tramadol (Mandolgin,
Mandoz A/S, Odense, Denmark); none of the subjects
had taken tramadol in the morning before any of the
two experiments.
Experiments and interventions
From all subjects, biopsies were obtained from trapezius
muscles before and after treatment with prednisolone; in
all patients, the trapezius muscle exhibited the symp-
toms characteristic of PMR, i.e. aching, tenderness and
stiffness. Following local anesthesia of the skin and sub-
cutis with Lidocaine (20 mg/mL), muscle tissue was
sampled through a small incision in the cutis, subcutis
and muscle fascia using a 5 mm Bergström needle
with suction [18]. Muscle samples were snap-frozen
in liquid nitrogen, weighed (wet weight ranged from
35 to 100 mg per sample), and stored at −80 °C until
RNA extraction.
Total RNA extraction
Total RNA was extracted from 20 to 30 mg muscle sam-
ple by tissue homogenization in TriReagent (Molecular
Table 1 Characteristics of the PMR patients and the non-PMR
control subjects
PMR patients
(n = 9)
Controls
(n = 10)
Female/male 5/4 5/5
Age, mean (range), years 74.2 (60.5–87.2) 72.3 (63.4–85.2)
Body–mass index, mean (range),
kg/m2
24.3 (16.5–28.7) 25.7 (22.1–29.3)
ESR, mean (range) mm/h
Before treatment 66 (43–74) † 9 (3–11)
After treatment 13 (4–23) ‡ 7 (4–10)
CRP, mean (range) mg/l
Before treatment 55 (27–131)† 2 (0–10)
After treatment 5 (0–11)‡ 2 (1–8)
† p < 0.05 vs. control subjects. ‡ p < 0.05 vs. untreated patients
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Research Center, Cincinnati, Ohio, US) using a bead-
mixer (FastPrep®-24 instrument, MP Biomedicals, Illkirch,
France) with five inert 2.3 mm steel beads (BioSpec Prod-
ucts, Bartlesville, OK, US) and one siliciumcarbid crystal
followed by addition of bromo-chloropropane to separate
the homogenate into aqueous and organic phases. To pre-
cipitate RNA, isopropanol was added to the isolated aque-
ous phase. The precipitated total RNA was washed
repeatedly in 75% ethanol and dissolved in RNAse-free
water before storing at −80 °C until further analysis. Total
RNA concentrations were determined by spectroscopy;
yields averaged 0.4 μg total RNA/mg muscle tissue.
DNA microarray analysis
Sample preparation and hybridization, and detection and
quantification of signals
Total RNA was further purified using RNeasy Mini Kits
(Qiagen, Valencia, CA, US), and the integrity and purity
of the RNA was verified using an Agilent Bioanalyser
(Agilent, Palo Alto, CA, US) as previously described
[19]. Based on the quality of the RNA, 8 patient samples
and 10 control subject samples were selected for micro-
array assessment. ds-cDNA was synthesized from 2 μg
total RNA using an oligo-dT primer containing a T7 RNA
polymerase promoter, and labeled in an T7 promoter-
driven in vitro transcription reaction producing biotin-
labeled cRNA from the cDNA according to the manufac-
turer’s (Affymetrix, Santa Clara, CA, US) guidelines. Next,
the hybridization mixture was prepared from the fragmen-
ted target cRNA as well as probe array controls, bovine
serum albumin, and herring sperm DNA.
Affymetrix GeneChip Human Genome U133 Plus 2.0
(Santa Clara, CA, US) arrays, which comprise 54,675
probe sets, were used. Following hybridization, the probe
arrays were washed and stained with phycoerytrin strep-
tavidin (SAPE) using the Affymetrix Fluidics Station 450
and scanned using an Affymetrix GeneArray 3000 7G
scanner 488 nm to generate fluoresecent images as
described in the Affymetrix GeneChip protocol. The
amount of bound target at each location of the probe
array is proportional to the amount of bound light emit-
ted at 570 nm. Scanned data were stored as image files
in cel-format.
Data analysis
Cel-files were imported into the statistical software pack-
age R v. 2.7.2 using BioConductor v. 2.8 [20], and gcRMA
modeled using quantiles normalization and median polish
summarization [21]. The modeled log-intensity of ap-
proximately 54,600 probe sets was used for selecting
differentially expressed genes. The microarray data were
submitted to the gene expression repository at Array Ex-
press (http://www.ebi.ac.uk/arrayexpress/) with accession
number E-MTAB-3671. Differentially expressed genes
were selected based on an initial two-way ANOVA ana-
lysis including the parameters disease (PMR versus con-
trol) and treatment (before versus after treatment) with a
p-value <0.05 and mutual fold change cut-off of 1.2 and
reflecting either main effect or intervention. The resulting
565 selected probe sets were further analyzed. Pairwise
differentially expressed transcripts were depicted by a uni-
variate two-sample t-test with equal variance. Multiple
testing corrections were performed using the multtest
package in Bioconducter v. 2.7.2. Control of Type I error
rate was performed by computing adjusted p-values for
simple multiple testing procedures from a vector of raw
(unadjusted) p-values by applying the Benjamini & Hoch-
berg FDR analysis [22]. Only transcripts exhibiting a fold
change larger than 1.2 and a difference of means larger
than 30 (real unlogged values) between (mutual) classes
were considered.
Gene grouping criteria
Predefined criteria were applied to identify genes of poten-
tial pathophysiological impact. The criteria were: 1. differ-
ence in expression level between untreated patients and
untreated controls (Table 2), and 2. response to prednisol-
one treatment of expression levels in a given direction in
patients only (Table 3). Those genes that differed between
untreated patients and controls and that also responded
to prednisolone treatment in patients, i.e. the aggregate of
criteria 1 and 2, were also identified (criterion 3) (Table 4).
Assessment of biological function
For genes in all three criteria sets, biological functions
were assessed using the Database for Annotation,
Visualization and Integrated Discovery (DAVID) tool
[23] with default options and annotations current as of
February 2013. Functional annotation clustering was
performed; this process associates individual genes in a
large gene list with biological terms and group sets of
genes according to functionally similar terms. Moreover,
the importance of each cluster is ranked using enrich-
ment scores, which are the geometric means of the en-
richment P values (EASE score [24]) for each annotation
term in the cluster. While enrichment scores above 1.3
are considered particularly interesting, clusters with
scores below 1.3 could also be of central importance
(e.g. short gene lists do not generally get very high en-
richment scores, illustrating that categories with lower
scores may still be biologically relevant) [23]. In the
presentation of the results, clusters with the highest en-
richment scores will be presented.
Quantitative RT-PCR
To confirm mRNA level fold differences and fold
changes found using the microarrays, mRNA levels for a
selection (Tables 5 and 6) of the filtered genes were
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Table 2 Genes the expression levels of which differed between untreated patients and untreated controls (78 genes)
Gene symbol Gene name Probe set(s) FDa p
BDNF brain-derived neurotrophic factor 244503_at +1.8 0.016
ETS2 v-ets erythroblastosis virus E26 oncogene homolog 2 (avian) 201328_at +1.8 0.007
SVIP small VCP/p97-interacting protein 230285_at +1.7 0.002
SH3RF2 SH3 domain containing ring finger 2 228892_at +1.6 0.004
TM4SF18 transmembrane 4 L six family member 18 230061_at +1.5 0.007
TMTC1 transmembrane and tetratricopeptide repeat containing 1 226322_at
226931_at
+1.5
+1.6
0.003
<0.001
TMEM18 transmembrane protein 18 225489_at +1.5 0.008
N4BP2L1 NEDD4 binding protein 2-like 1 213375_s_at +1.5 0.019
FMO2 flavin containing monooxygenase 2 (non-functional) 228268_at +1.5 0.002
RPL37 ribosomal protein L37 224763_at +1.5 <0.001
CTDSP2 CTD (carboxy-terminal domain. RNA polymerase II. polypeptide A)
small phosphatase 2
238999_at +1.4 0.048
RASL10B RAS-like. Family 10. member B 235488_at +1.4 0.012
SMG1P1 nuclear pore complex interacting protein-like 231989_s_at +1.4 0.008
ZNF331 zinc finger protein 331 219228_at +1.4 <0.001
FAM184B family with sequence similarity 184. member B 235288_at +1.4 0.013
LOC100507303 uncharacterized LOC100507303 228049_x_at +1.4 0.019
NCKIPSD NCK interacting protein with SH3 domain 218697_at +1.4 <0.001
ECHDC3 enoyl CoA hydratase domain containing 3 219298_at +1.3 0.049
RNF114 ring finger protein 114 200867_at
200868_s_at
211678_s_at
+1.3
+1.3
+1.2
0.006
0.023
0.018
TMPO thymopoietin 224944_at +1.3 0.002
RERE arginine-glutamic acid dipeptide (RE) repeats 200940_s_at +1.3 0.003
TUBD1 tubulin. Delta 1 231853_at +1.3 0.003
MARK4 MAP/microtubule affinity-regulating kinase 4 55065_at +1.3 0.005
ZNF195 zinc finger protein 195 204234_s_at +1.3 0.003
PCF11 PCF11. cleavage and polyadenylation factor subunit. Homolog
(S. cerevisiae)
203378_at +1.3 0.007
DFFA DNA fragmentation factor. 45 kDa. alpha polypeptide 226116_at +1.3 0.010
PSPC1 paraspeckle component 1 218371_s_at +1.3 0.007
RBBP6 retinoblastoma binding protein 6 212783_at +1.3 0.004
EIF4B eukaryotic translation initiation factor 4B 211937_at +1.3 0.017
NPM1 nucleophosmin (nucleolar phosphoprotein B23. numatrin) 221691_x_at +1.3 0.011
RSBN1 round spermatid basic protein 1 213694_at +1.2 0.003
PSIP1 PC4 and SFRS1 interacting protein 1 209337_at +1.2 0.010
EIF3G eukaryotic translation initiation factor 3. subunit G 208887_at +1.2 0.006
COL4A3BP collagen. Type IV. alpha 3 (Goodpasture antigen) binding protein 219625_s_at
223465_at
+1.2
+1.2
0.003
0.029
PCID2 PCI domain containing 2 219940_s_at +1.2 0.003
PXDC1 PX domain containing 1 212923_s_at +1.2 0.042
BCKDHA branched chain keto acid dehydrogenase E1, alpha polypeptide 202331_at +1.2 0.024
AKR7A2 aldo-keto reductase family 7, member A2 202139_at +1.2 0.010
MRPS2 mitochondrial ribosomal protein S2 218001_at +1.2 0.018
RORA RAR-related orphan receptor A 226682_at +1.2 0.049
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Table 2 Genes the expression levels of which differed between untreated patients and untreated controls (78 genes) (Continued)
RPL36AL ribosomal protein L36a-like 207585_s_at +1.2 0.011
TFRC transferrin receptor (p90, CD71) 208691_at –3.0 0.004
SFRP4 secreted frizzled-related protein 4 204051_s_at
204052_s_at
−2.9 0.001
0.002
NOV nephroblastoma overexpressed 214321_at −2.0 0.037
PAQR9 progestin and adipoQ receptor family member IX 1558322_a_at −2.0 <0.001
C2orf88 chromosome 2 open reading frame 88 228195_at −1.9 0.011
FAM69A family with sequence similarity 69, member A 213689_x_at −1.8 0.001
TP53INP2 tumor protein p53 inducible nuclear protein 2 224836_at −1.8
−1.9
<0.001
0.002
SH3KBP1 SH3-domain kinase binding protein 1 1554168_a_at
223082_at
−1.8 0.002
NINJ2 ninjurin 2 219594_at −1.7 0.039
MEST mesoderm specific transcript homolog (mouse) 202016_at −1.7 0.010
ITGB1BP2 integrin beta 1 binding protein (melusin) 2 219829_at −1.6 <0.001
PLXDC1 plexin domain containing 1 219700_at −1.5 0.006
BPGM 2,3-bisphosphoglycerate mutase 203502_at −1.5 <0.001
MTFP1 mitochondrial fission process 1 223172_s_at −1.5 0.004
MAP2K3 mitogen-activated protein kinase kinase 3 215499_at −1.5 0.003
LRRN4CL LRRN4 C-terminal like 1556427_s_at −1.4 0.042
FBXO9 F-box protein 9 210638_s_at212987_at −1.4
−1.4
<0.001
<0.001
HERC1 HECT and RLD domain containing E3 ubiquitin protein ligase
family member 1
218306_s_at −1.4 <0.001
JARID2 jumonji, AT rich interactive domain 2 203297_s_at −1.4 <0.001
TRAK1 trafficking protein, kinesin binding 1 202079_s_at −1.4 0.004
ZNF252P zinc finger protein 252, pseudogene 228200_at −1.4 <0.001
PRSS23 protease, serine, 23 202458_at −1.4 0.030
OLFML2B olfactomedin-like 2B 213125_at −1.4 0.049
MSANTD4 Myb/SANT-like DNA-binding domain containing 4 with coiled-coils 227418_at −1.3 0.043
ZDHHC7 zinc finger, DHHC-type containing 7 218606_at −1.3 <0.001
RAP2A RAP2A, member of RAS oncogene family 225585_at −1.3 0.016
LRP12 low density lipoprotein receptor-related protein 12 219631_at −1.3 0.050
BMPR1A bone morphogenetic protein receptor, type IA 213578_at −1.3 0.001
RNF10 ring finger protein 10 207801_s_at −1.3 <0.001
COL5A1 collagen, type V, alpha 1 203325_s_at −1.3 0.007
INSIG1 insulin induced gene 1 201626_at −1.3 0.046
SLC35E3 solute carrier family 35, member E3 218988_at −1.3 0.003
MEMO1 dpy-30 homolog (C. elegans) /// mediator of cell motility 1 219065_s_at −1.3 0.004
MYL4 myosin, light chain 4, alkali; atrial, embryonic 210395_x_at −1.2 0.002
COX7A2 cytochrome c oxidase subunit VIIa polypeptide 2 (liver) 201597_at −1.2 0.019
MGAT4B mannosyl (alpha-1,3-)-glycoprotein beta-1,4-N-acetylglucosaminyltransferase,
isozyme B
224598_at −1.2 0.003
MRC2 mannose receptor, C type 2 209280_at −1.2 0.010
FD fold difference. a fold differences for genes with more than one probe set were calculated as the average of the individual values, which did not
differ markedly
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Table 3 Genes the expression levels of which responded to prednisolone treatment in a given direction only in patients with
polymyalgia rheumatica (131 genes)
Gene symbol Gene name Probe set(s) FCa p
COL1A1 collagen, type I, alpha 1 1556499_s_at +4.7 0.028
CTGF connective tissue growth factor 209101_at +2.9 0.012
MEST mesoderm specific transcript homolog (mouse) 202016_at +2.7 0.049
CDH11 cadherin 11, type 2, OB-cadherin (osteoblast) 207173_x_at +2.6 0.012
S1PR3 sphingosine-1-phosphate receptor 3 228176_at +2.5 0.009
CD248 CD248 molecule, endosialin 219025_at +2.5 0.019
FBN1 fibrillin 1 202766_s_at
235318_at
+2.4
+2.1
0.031
0.017
NINJ2 ninjurin 2 219594_at +2.3 0.002
MFAP5 microfibrillar associated protein 5 209758_s_at
213764_s_at
213765_at
+2.7
+2.2
+2.1
0.038
0.010
0.018
SH3PXD2B SH3 and PX domains 2B 231823_s_at +2.2 0.011
C13orf33 chromosome 13 open reading frame 33 227058_at +2.2 0.044
FOSL2 FOS-like antigen 2 218880_at +2.2 0.026
BGN biglycan 201261_x_at +2.1 0.029
NEDD9 neural precursor cell expressed, developmentally
down-regulated 9
233223_at +2.1 0.004
COL5A2 collagen, type V, alpha 2 221730_at +2.0 0.049
NT5E 5′-nucleotidase, ecto (CD73) 203939_at +2.0 0.044
TUBB6 tubulin, beta 6 class V 209191_at +2.0 0.031
SPARC secreted protein, acidic, cysteine-rich (osteonectin) 200665_s_at +2.0 0.043
FN1 fibronectin 1 210495_x_at
211719_x_at
212464_s_at
216442_x_at
+1.9
+1.9
+1.9
+2.0
0.045
0.042
0.046
0.038
GFPT2 glutamine-fructose-6-phosphate transaminase 2 205100_at +1.9 0.034
NFKBIZ nuclear factor of kappa light polypeptide gene enhancer
in B-cells inhibitor, zeta
223217_s_at +1.9 0.025
DCLK1 doublecortin-like kinase 1 205399_at +1.9 0.034
METRNL meteorin, glial cell differentiation regulator-like 225955_at +1.9 0.023
COL1A2 collagen, type I, alpha 2 229218_at +1.8 0.048
LAMB1 laminin, beta 1 201505_at +1.8 0.003
LSP1P1 lymphocyte-specific protein 1 pseudogene 214110_s_at +1.8 0.020
COL6A3 collagen, type VI, alpha 3 201438_at +1.8 0.003
GAS7 growth arrest-specific 7 202191_s_at
202192_s_at
+1.8
+1.7
0.028
0.021
ARHGAP26 Rho GTPase activating protein 26 244548_at +1.8 0.003
OLFML2B olfactomedin-like 2B 213125_at +1.7 0.031
SPON2 spondin 2, extracellular matrix protein 218638_s_at +1.7 0.002
COL6A1 collagen, type VI, alpha 1 213428_s_at +1.7 0.006
CILP cartilage intermediate layer protein, nucleotide
pyrophosphohydrolase
206227_at +1.7 0.012
OLFML3 olfactomedin-like 3 218162_at +1.7 0.026
FAM69A family with sequence similarity 69, member A 213689_x_at +1.7 <0.001
CORO1C coronin, actin binding protein, 1C 222409_at +1.6 0.020
MAP1B microtubule-associated protein 1B 226084_at +1.6 0.039
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Table 3 Genes the expression levels of which responded to prednisolone treatment in a given direction only in patients with
polymyalgia rheumatica (131 genes) (Continued)
COL6A2 collagen, type VI, alpha 2 209156_s_at +1.6 0.020
PRKCDBP protein kinase C, delta binding protein 213010_at +1.6 <0.001
CLIC4 chloride intracellular channel 4 201560_at +1.6 0.010
LRRN4CL LRRN4 C-terminal like 1556427_s_at +1.5 0.006
CD109 CD109 molecule 226545_at +1.5 0.034
DBN1 drebrin 1 202806_at +1.5 0.020
SFXN3 sideroflexin 3 220974_x_at +1.5 0.016
TNXA / TNXB tenascin XA (pseudogene) / tenascin XB 206093_x_at
213451_x_at
216333_x_at
+1.5
+1.5
+1.5
0.030
0.034
0.041
PRSS23 protease, serine, 23 202458_at +1.5 0.022
TUBA1A tubulin, alpha 1a 209118_s_at +1.5 0.038
SAMHD1 SAM domain and HD domain 1 235529_x_at +1.5 0.024
ITGB1BP2 integrin beta 1 binding protein (melusin) 2 219829_at +1.5 0.003
ATP2C1 ATPase, Ca++ transporting, type 2C, member 1 209934_s_at +1.5 <0.001
PXDC1 PX domain containing 1 212923_s_at +1.5 0.014
PAQR9 progestin and adipoQ receptor family member IX 1558322_a_at +1.4 0.027
P4HA2 prolyl 4-hydroxylase, alpha polypeptide II 202733_at +1.4 0.024
ANXA2 annexin A2 201590_x_at
210427_x_at
213503_x_at
+1.4
+1.4
+1.4
0.025
0.027
0.032
ACVRL1 activin A receptor type II-like 1 226950_at +1.4 0.009
CHSY1 chondroitin sulfate synthase 1 203044_at +1.4 0.021
C10orf54 chromosome 10 open reading frame 54 225373_at +1.4 0.016
PLAGL1 pleiomorphic adenoma gene-like 1 207943_x_at +1.4 0.012
CTTNBP2NL CTTNBP2 N-terminal like 226000_at +1.4 0.019
SYNPO2 synaptopodin 2 225720_at +1.4 0.013
ANXA2P2 annexin A2 pseudogene 2 208816_x_at +1.4 0.042
TGFB1I1 transforming growth factor beta 1 induced transcript 1 209651_at +1.4 0.043
ACTB actin, beta 213867_x_at
224594_x_at
200801_x_at
+1.4
+1.4
+1.4
0.048
0.040
0.033
TRIO triple functional domain (PTPRF interacting) 208178_x_at
209012_at
+1.4 0.018
ITGA5 integrin, alpha 5 (fibronectin receptor, alpha polypeptide) 201389_at +1.4 0.038
RRBP1 ribosome binding protein 1 homolog 180 kDa (dog) 201204_s_at +1.4 0.010
LASP1 LIM and SH3 protein 1 200618_at +1.4 0.016
ADNP2 ADNP homeobox 2 203321_s_at +1.3 0.009
MTFP1 mitochondrial fission process 1 223172_s_at +1.3 0.017
TP53INP2 tumor protein p53 inducible nuclear protein 2 224836_at +1.3 0.017
PDGFRB platelet-derived growth factor receptor, beta polypeptide 202273_at +1.3 0.009
FBXO9 F-box protein 9 210638_s_at
212987_at
+1.3
+1.3
0.002
<0.001
VAT1 vesicle amine transport protein 1 homolog (T. californica) 208626_s_at +1.3 0.043
LTBP1 latent transforming growth factor beta binding protein 1 202729_s_at +1.3 0.026
HIF1A hypoxia inducible factor 1, alpha subunit 200989_at +1.3 0.025
SH3KBP1 SH3-domain kinase binding protein 1 1554168_a_at +1.3 0.044
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Table 3 Genes the expression levels of which responded to prednisolone treatment in a given direction only in patients with
polymyalgia rheumatica (131 genes) (Continued)
223082_at +1.3 0.027
JARID2 jumonji, AT rich interactive domain 2 203297_s_at +1.3 0.007
ACTG1 actin, gamma 1 201550_x_at
211970_x_at
211983_x_at
211995_x_at
212363_x_at
212988_x_at
213214_x_at
+1.3
+1.3
+1.3
+1.3
+1.3
+1.3
+1.3
0.015
0.009
0.031
0.013
0.020
0.017
0.021
MAP2K3 mitogen-activated protein kinase kinase 3 215499_at +1.3 0.021
MEMO1 mediator of cell motility 1 219065_s_at +1.3 0.012
EZR ezrin 208623_s_at +1.3 0.002
BPGM 2,3-bisphosphoglycerate mutase 203502_at +1.2 0.036
TUBB tubulin, beta class I 212320_at +1.2 0.039
DDAH1 dimethylarginine dimethylaminohydrolase 1 209094_at +1.2 0.033
BDNF brain-derived neurotrophic factor 244503_at −3.1 0.001
SLC25A34 solute carrier family 25, member 34 1559977_a_at
232245_at
−1.9
−1.9
0.006
0.009
SVIP small VCP/p97-interacting protein 230285_at −1.7 0.004
VPS8 vacuolar protein sorting 8 homolog (S. cerevisiae) 239917_at −1.6 <0.001
PIAS2 protein inhibitor of activated STAT, 2 244633_at −1.6 0.011
LOC100507303 uncharacterized LOC100507303 228049_x_at −1.6 0.004
RPL37 ribosomal protein L37 224763_at −1.5 <0.001
TMTC1 transmembrane and tetratricopeptide repeat containing 1 226322_at
226931_at
−1.4
−1.6
0.005
<0.001
MLYCD malonyl-CoA decarboxylase 218869_at −1.5 0.004
UCP3 uncoupling protein 3 (mitochondrial, proton carrier) 207349_s_at −1.5 0.016
TUBD1 tubulin, delta 1 231853_at −1.4 0.003
BCKDHA branched chain keto acid dehydrogenase E1, alpha
polypeptide
202331_at −1.4 0.004
TRIM39 tripartite motif containing 39 222732_at −1.4 0.002
ZNF331 zinc finger protein 331 219228_at −1.4 0.003
NRBF2 nuclear receptor binding factor 2 223650_s_at −1.4 0.021
GTF2H5 general transcription factor IIH, polypeptide 5 244294_at −1.4 0.007
FMO2 flavin containing monooxygenase 2 (non-functional) 228268_at −1.4 0.002
TMEM18 transmembrane protein 18 225489_at −1.4 0.028
HSDL2 Hydroxysteroid dehydrogenase like 2 215436_at −1.4 0.006
N4BP2L1 NEDD4 binding protein 2-like 1 213375_s_at −1.4 0.033
PEBP4 phosphatidylethanolamine-binding protein 4 227848_at −1.4 0.009
RANBP9 RAN binding protein 9 216125_s_at −1.4 0.002
ST3GAL5 ST3 beta-galactoside alpha-2,3-sialyltransferase 5 203217_s_at −1.3 0.003
ACADSB acyl-CoA dehydrogenase, short/branched chain 226030_at −1.3 0.006
RNF114 ring finger protein 114 200867_at
200868_s_at
211678_s_at
−1.3
−1.3
−1.2
0.020
0.030
0.041
MRPS2 mitochondrial ribosomal protein S2 218001_at −1.3 0.006
TMEM50B transmembrane protein 50B 219600_s_at −1.3 0.027
EIF3G eukaryotic translation initiation factor 3, subunit G 208887_at −1.3 0.005
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measured using quantitative real-time PCR (qRT-PCR).
Moreover, mRNA levels for additional genes (Table 5)
that did not differ using microarrays, but which were of
particular interest in elucidating the PMR disease mech-
anisms, were included in the qRT-PCR analysis.
From 9 patient samples and 9 control subject samples,
cDNA was synthesized using Omniscript reverse tran-
scriptase (Qiagen, Hilden, Germany) from 500 ng total
RNA (same pool as used in the microarray runs) in 20 μl.
For each target mRNA, 0.25 μl cDNA was amplified in
25 μl Quantitect SYBR Green Master Mix (Qiagen) with
corresponding primers (100 nM of both antisense and
sense primers, Table 6) on a Stratagene MX3000P RT-
PCR instrument (Stratagene, La Jolla, CA, US).
The applied thermal profile was as follows: 95°Celsius,
10 min-(95 °C, 15 s-58 °C, 30s-63°C, 90s)×50–95 °C,
60s-55°C, 30s-95°C, 60s. Standard curves were made
using dilution series of a cDNA pool and related to the
threshold cycles (Ct) at the 63 °C step at which the signal
intensity was acquired. To ensure specificity, melting
curves were analyzed post amplification (at the 55 °C to
95 °C step). The Ct values for the samples were con-
verted to relative values using the standard curves and
normalized to the internal “housekeeping” control,
ribosomal protein P0 (RPLP0). Microarray analysis
confirmed that the RPLP0 mRNA level is stable under
the current conditions and therefore suitable as the
normalizer.
Statistics
Statistical methods used in the evaluation of the micro-
array data are described above. Data are reported in
compliance with the guidelines for minimum informa-
tion about a microarray experiment (MIAME).
Statistical analyses of qRT-PCR and anthropometric
data as well as of ESR and CRP levels were performed
using SPSS software version 20.0 for Macintosh. qRT-
PCR data were log-transformed. Statistically significant
differences were detected using Student’s t tests,
paired or unpaired as applicable. Identical conclusions
were achieved with standard non-parametric tests. P-
values less than 0.05 were considered significant in
two-tailed testing.
Results
Clinical characteristics for all participants are given in
Table 1. In all of the PMR patients, treatment with pred-
nisolone abolished symptoms within a few days, support-
ing the PMR diagnosis; at day 15, ESR and CRP levels
were markedly reduced in the patients and did no longer
differ significantly from values in controls (Table 1).
Table 3 Genes the expression levels of which responded to prednisolone treatment in a given direction only in patients with
polymyalgia rheumatica (131 genes) (Continued)
PSIP1 PC4 and SFRS1 interacting protein 1 209337_at −1.3 0.007
PTP4A1 protein tyrosine phosphatase type IVA, member 1 200732_s_at −1.3 <0.001
EIF4B eukaryotic translation initiation factor 4B 211937_at −1.3 0.015
FAM184B family with sequence similarity 184, member B 235288_at −1.3 0.042
CNNM3 cyclin M3 229031_at −1.3 0.011
RERE arginine-glutamic acid dipeptide (RE) repeats 200940_s_at −1.3 0.008
ZNF195 zinc finger protein 195 204234_s_at −1.3 0.002
SNRPA small nuclear ribonucleoprotein polypeptide A 201770_at −1.3 0.025
TM4SF18 transmembrane 4 L six family member 18 230061_at −1.3 0.033
RPL36AL ribosomal protein L36a-like 207585_s_at −1.2 0.008
RBBP6 retinoblastoma binding protein 6 212783_at −1.2 0.025
TSFM Ts translation elongation factor, mitochondrial 214331_at −1.2 0.019
POLR1B polymerase (RNA) I polypeptide B, 128 kDa 223403_s_at −1.2 0.018
NPM1 nucleophosmin (nucleolar phosphoprotein B23, numatrin) 221691_x_at −1.2 0.022
OXA1L oxidase (cytochrome c) assembly 1-like 208717_at −1.2 0.027
RSBN1 round spermatid basic protein 1 213694_at −1.2 0.016
AKR7A2 aldo-keto reductase family 7, member A2 202139_at −1.2 0.002
RORA RAR-related orphan receptor A 226682_at −1.2 0.044
DFFA DNA fragmentation factor, 45 kDa, alpha polypeptide 226116_at −1.2 0.016
FC, fold change. Entries in bold indicate that genes also responded significantly (but in the opposite direction) in control subjects. Responses in controls for both
these genes, TNXA/TNXB and RORA, were of the same magnitude as in patients but in the opposite direction. afold changes for genes with more than one probe
set were calculated as the average of the individual values, which did not differ markedly
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Table 4 Genes the expression levels of which differed between untreated patients with polymyalgia rheumaticaand untreated
controls (FD), and which responded to prednisolone treatment in the patients (FC) (44 genes)
Gene symbol Gene name FDa p FCb p
BDNF brain-derived neurotrophic factor +1.8 0.016 −3.1 0.001
SVIP small VCP/p97-interacting protein +1.7 0.002 −1.7 0.004
TM4SF18 transmembrane 4 L six family member 18 +1.5 0.007 −1.3 0.033
TMTC1 transmembrane and tetratricopeptide repeat containing 1 +1.5 0.001 −1.5 0.003
TMEM18 transmembrane protein 18 +1.5 0.008 −1.4 0.028
N4BP2L1 NEDD4 binding protein 2-like 1 +1.5 0.019 −1.4 0.033
FMO2 flavin containing monooxygenase 2 (non-functional) +1.5 0.002 −1.4 0.012
RPL37 ribosomal protein L37 +1.5 <0.001 −1.5 <0.001
FAM184B family with sequence similarity 184, member B +1.4 0.013 −1.3 0.042
LOC100507303 uncharacterized LOC100507303 +1.4 0.019 −1.6 0.004
RNF114 ring finger protein 114 +1.3 0.016 −1.3 0.030
RERE arginine-glutamic acid dipeptide (RE) repeats +1.3 0.003 −1.3 0.008
TUBD1 tubulin, delta 1 +1.3 0.003 −1.4 0.003
ZNF195 zinc finger protein 195 +1.3 0.003 −1.3 0.002
DFFA DNA fragmentation factor, 45 kDa, alpha polypeptide +1.3 0.010 −1.2 0.016
RBBP6 retinoblastoma binding protein 6 +1.3 0.004 −1.2 0.025
NPM1 nucleophosmin (nucleolar phosphoprotein B23, numatrin) +1.3 0.011 −1.2 0.022
EIF4B eukaryotic translation initiation factor 4B +1.3 0.017 −1.3 0.015
RSBN1 round spermatid basic protein 1 +1.2 0.003 −1.2 0.016
PSIP1 PC4 and SFRS1 interacting protein 1 +1.2 0.010 −1.3 0.007
EIF3G eukaryotic translation initiation factor 3, subunit G +1.2 0.006 −1.3 0.005
PXDC1 PX domain containing 1 +1.2 0.042 +1.5 0.014
BCKDHA branched chain keto acid dehydrogenase E1, alpha polypeptide +1.2 0.024 −1.4 0.004
AKR7A2 aldo-keto reductase family 7, member A2 +1.2 0.010 −1.2 0.002
MRPS2 mitochondrial ribosomal protein S2 +1.2 0.018 −1.3 0.006
RORA RAR-related orphan receptor A +1.2 0.049 −1.2 0.044
RPL36AL ribosomal protein L36a-like +1.2 0.011 −1.2 0.008
PAQR9 progestin and adipoQ receptor family member IX −2.0 <0.001 +1.4 0.027
FAM69A family with sequence similarity 69, member A −1.8 0.001 +1.7 <0.001
TP53INP2 tumor protein p53 inducible nuclear protein 2 −1.8 <0.001 +1.3 0.017
SH3KBP1 SH3-domain kinase binding protein 1 −1.8 0.002 +1.3 0.035
NINJ2 ninjurin 2 −1.7 0.039 +2.3 0.002
MEST mesoderm specific transcript homolog (mouse) −1.7 0.010 +2.7 0.049
ITGB1BP2 integrin beta 1 binding protein (melusin) 2 −1.6 <0.001 +1.5 0.003
BPGM 2,3-bisphosphoglycerate mutase −1.5 <0.001 +1.2 0.036
MTFP1 mitochondrial fission process 1 −1.5 0.004 +1.3 0.017
MAP2K3 mitogen-activated protein kinase kinase 3 −1.5 0.003 +1.3 0.021
LRRN4CL LRRN4 C-terminal like −1.4 0.042 +1.5 0.006
FBXO9 F-box protein 9 −1.4 <0.001 +1.3 0.001
JARID2 jumonji, AT rich interactive domain 2 −1.4 <0.001 +1.3 0.007
PRSS23 protease, serine, 23 −1.4 0.030 +1.5 0.022
OLFML2B olfactomedin-like 2B −1.4 0.049 +1.7 0.031
MEMO1 mediator of cell motility 1 −1.3 0.004 +1.3 0.012
FD fold difference, FC fold change
a + and −; expression levels were higher and lower, respectively, in patients with polymyalgia rheumatica than in controls before treatment with prednisolone
b + and −; expression levels increased and decreased, respectively, in patients with polymyalgia rheumatica after treatment with prednisolone
Entry in bold indicates that the gene also responded significantly to prednisolone in controls. The response in controls for the RORA gene was of the same
magnitude as in patients but in the opposite direction
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Control subjects had normal ESR and CRP values both
before and after treatment (Table 1).
Differential expression of genes in untreated PMR
patients vs controls
565 transcripts were differentially expressed between pa-
tients and controls or before vs after treatment with
prednisolone, reflecting either main effect or interaction.
Among these transcripts, 165 genes fulfilled at least one
of the 2 criteria (Methods) that define the potentially,
clinically relevant genes.
Of the 165 genes, expression levels of 78 genes dif-
fered between patients and controls before treatment
(Fig. 1, Table 2). Among these genes, 41 genes were up-
regulated in the patients (mean fold difference: 1.4;
range: 1.2–1.8), while 37 were downregulated (mean fold
difference: 1.5; range: 1.2 − 3.0).
In this subset, the biological function (Fig. 2) of the 78
genes as identified by the DAVID functional annotation
clusters (19 clusters in total) included translation/protein
biosynthesis (2 clusters, enrichment scores 0.8 and 0.62
[data not shown), transcription/regulation of transcrip-
tion (2 clusters, enrichment score 0.69 and 0.4 [data not
shown), nuclear transport and protein transport (enrich-
ment score 0.83), and SH3 domain binding properties
(enrichment score 1.15 [data not shown).
Genes responding to prednisolone in PMR patients
Expression of 131 of the total 165 genes responded to
prednisolone treatment in patients (Fig. 1 and Table 3); of
these genes, two responded significantly to treatment in
controls, however in the opposite direction to that seen in
patients. Of the 131 genes, the expression of 84 genes was
up-regulated upon treatment (mean fold change: 1.7;
range: 1.2–4.7); 47 genes were down-regulated (mean fold
difference: 1.4; range: 1.2–3.1). In this subset, out of a total
of 62 DAVID-identified clusters, the clusters of interesting
biological function and high enrichment scores (Fig. 3) in-
cluded extracellular matrix organization and cell adhesion
(2 highly enriched clusters, enrichment scores 5.58 and
4.11 [not shown in Fig. 3]), cytoskeleton/microtubule
organization (2 clusters, enrichment scores 2.38 and 1.62
[not shown in Fig. 3]), and actin filament/cytoskeleton as-
sociated processes (1 cluster, enrichment score 1.57).
Genes differentially expressed in untreated PMR patients
vs controls and also responding to prednisolone in
patients
Among all 165 differentially expressed genes were 44
genes, the expression levels of which differed between
untreated patients and controls and which in patients
only also responded to prednisolone treatment in a given
direction (Fig. 1 and Table 4). Of these 44 genes, the ex-
pression levels of 28 genes were higher in untreated pa-
tients than in untreated controls (mean fold difference:
1.4; range: 1.2–1.8); the expression levels of 16 genes
were lower (mean fold difference: 1.4; range: 1.2–2.0).
Upon prednisolone treatment, the expression levels of
27 were down-regulated in patients (mean fold change:
1.4; range: 1.2–3.1), whereas 17 genes were up-regulated
(mean fold change: 1.5; range: 1.2–2.7). None of the 44
genes responded significantly to prednisolone treatment
in control subjects.
In this subset, out of a total of 8 DAVID-identified clus-
ters, the clusters with the highest enrichment scores (Fig. 4)
comprised genes with transcription regulation (2 clusters,
enrichment scores 1.59 and 1.17 [data not shown) and pro-
tein translation/biosynthesis (2 clusters, enrichment score
0.63 and 0.59 [data not shown) properties.
Table 5 Quantitative RT-PCR fold differences between
untreated patients with polymyalgia rheumatica (PMR) and
non-PMR controls, and fold changes between treated and
untreated PMR patients
Gene symbol Fold differencesb Fold changesc
(probe name) qRT-PCR Microarraya qRT-PCR Microarraya
Genes that differed in microarray testing in at least one comparison
BDNF +1.90* +1.80 * −1.58 ** −3.1 **
COL5A1 −1.33 ns −1.30 ** +1.73 ns +2.30 ns
EIF4B +1.63 p = 0.0504 +1.30 * −1.23 * −1.30 *
MARK4 +1.32 ns +1.30 ** −1.24 * −1.15 ns
MTFP1 +1.00 ns −1.50 ** +1.33 * +1.30 *
NPM1 +1.38 ** +1.30 * −1.09 ns −1.22 *
PRSS23 −1.21 ns −1.40 * +1.27 ns +1.51 *
TFRC −1.63 ns −3.00 * +1.17 ns +1.76 ns
TUBD1 +1.26 ** +1.30 ** −1.08 ns −1.40 **
Genes that did not differ in microarray testing
ACTA1
(203872_at)
−1.03 ns −1.02 ns 1.06 ns +1.00 ns
DESa
(216947_at
202222_s_at
214027_x_at)
+1.16 ns +1.00 ns −1.07 ns +1.00 ns
IL6
(205207_at)
+4.54 * +1.02 ns −3.25 * +1.02 ns
TNFA
(207113_s_at)
+1.31 ns +1.00 ns −1.31 ns −1.00 ns
TUBA8
(220069_at)
−1.02 ns −1.02 ns +1.10 ns +1.00 ns
qRT-PCR quantitative real-time PCR
* p < 0.05. ** p < 0.01. ns, not statistically significant. Data are geometric means
a Microarray numbers were calculated as the mean of the individual
probe values
b + and −, expression levels were higher and lower, respectively, in patients
with polymyalgia rheumatica than in controls before treatment
with prednisolone
c + and −, expression levels increased and decreased, respectively, in patients
with polymyalgia rheumatica after treatment with prednisolone
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Table 6 qRT-PCR primer sequences
Gene Sense Antisense
ACTA1 GCCGTGTTCCCGTCCATCGT TTCAGGGTCAGGATACCTCTCTTGCT
BDNF GAGGGGAGCTGAGCGTGTGTG TTTTTGTCTGCCGCCGTTACCC
COL5A1 CGCCGACACCTCCAACTCCTC CTCAGTGAACTCCCCCTCCAA
DES CCATCCAGACCTACTCTGCCCTC TTGGTATGGACCTCAGAACCCCTTT
EIF4B CGTCAGCTGGATGAGCCAAAA GTCCTCGACCGTTCCCGTTCC
IL6 GAGGCACTGGCAGAAAACAACC CCTCAAACTCCAAAAGACCAGTGATG
MARK4 AGATCCCAGAGCGGCGGAAG GGGTCATCATGCTAGGAGGGAGGTT
MTFP1 AAGGCAAGAAGGCTGGAGAGGTG ACAGAGGCTAGAGCCTGCCATACAAA
NPM1 GGTTTCCCTTGGGGGCTTTG GCACTGGCCCTGAACCACACTT
PRSS23 CAGCGGGTCTGGGGTCTATG GCCAATAATTTTTCGCTCCCACTTCT
TUBD1 TGATTGTTGGGAAGGCATGGA CAACAACCTGCTCTAATGACGTGAAA
TFRC TCGGGAATGCTGAGAAAACAGACA TTTTGGAGATACGTAGGGAGAGAGGAA
TNFA TTCCCCAGGGACCTCTCTCTAATC GAGGGTTTGCTACAACATGGGCTAC
TUBA8 GCCCAAGGATGTGAATGTCGCT GGTCGGGGGCTGGTAGTTGATG
RPLP0 GGAAACTCTGCATTCTCGCTTCCT CCAGGACTCGTTTGTACCCGTTG
qRT-PCR quantitative real-time PCR
The primer set sequence for BDNF provided in Table 6 recognizes all BDNF isoforms; using this primer set, the results presented in Table 5 were obtained. The
BDNF mRNA levels were also assessed with qRT-PCR using a BDNF primer set that specifically recognizes the BDNF isoform that is recognized by the probe on the
used microarray; the results (fold difference + 1.53, p < 0.1; fold change −2.4, p < 0.01) from this additional assessment were very similar to the results presented
in Table 5
Fig. 1 Venn-diagram showing 1. the number of genes that differed between untreated patients with polymyalgia rheumatica (PMR) and non-PMR
controls (left circle, 34 + 44 genes) and 2. the number of genes that responded to treatment with prednisolone in a given direction in patients with
PMR only (right circle, 44 + 87 genes). The overlap of the two circles includes the number of genes which fulfilled both criteria 1 and 2 (44)
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qRT-PCR
To validate the levels found using microarrays, the ex-
pression of some of the genes were measured using
qRT-PCR (Tables 5 and 6, and Fig. 5).
Nine genes that fulfilled criterion 1 or criterion 2 ac-
cording to microarray analysis were examined with qRT-
PCR (Table 5 and Fig. 5b); 8 of the 9 genes were always
regulated in the same direction as found using microar-
rays. However, for the comparison of patients and controls
before treatment (criterion 1), the expression fold differ-
ences of 5 genes (COL5A1, MARK4, MTFP1, PRSS23, and
TRFC), which were statistically significant in the micro-
array analysis, did not reach significance using qRT-PCR
(p > 0.05). For the treated vs untreated patients comparison
(criterion 2), the fold changes for NPM1, PRSS23 and
TUBD1 were significant in the microarray but not in the
qRT-PCR, whereas the fold change for MARK4 was signifi-
cant only in qRT-PCR analysis. The fold changes for
COL5A1 and TRFC were not statistically significant
(p > 0.05) in the microarray nor in the qRT-PCR analysis.
Moreover, the expression levels of 5 genes (Table 5)
of potential interest in PMR that did not differ in the
microarray analysis were measured using qRT-PCR.
Expression levels of IL-6 (Fig. 5a), which did not dif-
fer in the microarray experiments (FD and FC < 1.1),
markedly differed both between untreated patients
and controls (FD 4.54, p < 0.05) and between patients
before and after treatment (FC —3.25, p < 0.05) using
qRT-PCR (Table 5). The remaining four genes were
found to differ neither between untreated patients
and controls nor between patients before and after
treatment with either method.
a b c
Fig. 2 Selected clusters of similar biologic functional terms for genes, the expression of which differed between untreated patients with polymyalgia
rheumatica (PMR) and non-PMR control subjects. The clusters and the enrichment scores (the geometric means of the EASE scores [24] of all terms in the
cluster) were derived using the Database for Annotation, Visualization and Integrated Discovery (DAVID) tool [23]. Green squares denote that the gene/term
association has been positively reported; black squares denote that the gene/term association has not yet been reported. a Cluster with an overall theme
of translation/protein biosynthesis and with an enrichment score of 0.8. b Cluster with an overall theme of (nuclear) protein transport associated processes
and with an enrichment score of 0.83. c Cluster with an overall theme of gene expression/transcription regulatory processes and with an enrichment score
of 0.69
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Discussion
In the present study, the gene expression in skeletal
muscle was measured for the first time in patients with
PMR and in non-PMR, matched controls subjects before
and after brief, symptom-relieving prednisolone treat-
ment using DNA microarrays. Microarray findings were
supplemented by testing of the expression levels of se-
lected genes with qRT-PCR, which was also used to
accurately measure expression levels of genes of particu-
lar interest. In all subjects, biopsies were obtained from
the trapezius muscle. Before treatment, patients had
marked clinical symptoms, including trapezius myalgia
and tenderness, as well as elevated ESR and levels of
CRP; upon treatment, paraclinical parameters had nor-
malized and clinical symptoms had disappeared.
Subjects were studied in 2008; thus, we were not able
to use the most recent PMR criteria, which were pub-
lished in 2012 [17]. However, the latter criteria are still
provisional and awaiting further validation, and, in the
most recent reviews of PMR, the Chuang criteria are
mentioned on par with the newer provisional criteria [2,
3, 8, 17]. The two criteria sets are very similar; however,
the fact that the demand for a high ESR is stricter in the
Chuang criteria implies that the patients in the present
study would also be accepted with the new criteria.
A total of 565 genes were differentially expressed
across all groups. In general, when measured by micro-
array, fold differences and fold changes in expression
were modest, ranging from 1.2 (cut-off value) to 1.4 for
most genes. Despite the relatively modest differences in
gene expression levels, gene function analysis indicated
that even these small differences may have a patho-
physiological and phenotypic impact in PMR. A few
genes were regulated more markedly, with fold differ-
ences and changes in the range of 2 to 4. In the micro-
array measurements, none of the genes that usually are
associated with PMR [12], for example genes encoding
proteins involved in inflammation, e.g. IL-6, were
a b c
Fig. 3 Selected clusters of similar biologic functional terms for genes, the expression of which responded to treatment with prednisolone in a
given direction only in patients with polymyalgia rheumatica (PMR); two of the genes in this group of genes (n = 131) also responded in non-
PMR controls, but in the opposite direction to that seen in patients. The clusters and the enrichment scores (the geometric means of the EASE
scores [24] of all terms in the cluster) were derived using the Database for Annotation, Visualization and Integrated Discovery (DAVID) tool [23].
Green squares denote that the gene/term association has been positively reported; black squares denote that the gene/term association has not
yet been reported. a Cluster with an overall theme of extracellular matrix/cell adhesion processes and with an enrichment score of 5.58. b Cluster
with an overall theme of cytoskeleton/microtubule associated processes and with an enrichment score of 2.38. c Cluster with an overall theme of
cytoskeleton/actin filament associated processes and with an enrichment score of 1.57
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differentially expressed in symptom-yielding muscle tis-
sue. However, using the more sensitive qRT-PCR tech-
nique, the expression of the IL6 gene showed marked
differences between groups, being up-regulated in un-
treated patients and down-regulated after prednisolone
treatment (Fig. 5). This finding is in line with a previous
microdialysis study that indicated a local production of
IL-6 in symptom-yielding muscles in patients with PMR,
and normalization with prednisolone treatment [5]. Fur-
thermore, several studies [1, 4, 5, 25] have found that
plasma IL-6 is highly elevated in PMR. In line with a key
role in the pathophysiology of the disease, IL-6 blockade
has recently in an open-label study been shown to be an
effective treatment for newly diagnosed PMR [26].
Genes differentially expressed in untreated PMR patients
vs controls
The applied study design allowed for 3 important com-
parisons. Firstly, by comparing expressions levels in
untreated patients and control subjects, 78 genes of pos-
sible central importance for the phenotype of PMR were
identified.
Although the enrichment scores, which are propor-
tional to the extent to which the cluster is represented
in the gene set (here 78 genes), were modest within this
subset of genes, functional clustering analysis identified
several clusters of genes, many of which were associated
with protein translation and biosynthesis. Other identi-
fied clusters included regulation of transcription, cellular
and nuclear protein transport, and rearrangement of the
cytoskeleton; the latter process was also represented in a
gene cluster that involved SH-3-domain-binding proper-
ties, which are associated with cytoskeletal elements and
signaling proteins.
The identification of clusters associated with protein
translation, biosynthesis and transport may suggest that
PMR is associated with abnormal protein metabolism
in muscle. It might be speculated that inflammation
a b
Fig. 4 Selected clusters of similar biologic functional terms for genes, the expression of which differed between patients with polymyalgia
rheumatica (PMR) and non-PMR control subjects before prednisolone treatment and which also responded to treatment with prednisolone in a
given direction only in PMR patients. The clusters and the enrichment scores (the geometric means of the EASE scores [24] of all terms in the
cluster) were derived using the Database for Annotation, Visualization and Integrated Discovery (DAVID) tool [23]. Green squares denote that the
gene/term association has been positively reported; black squares denote that the gene/term association has not yet been reported. a Cluster
with an overall theme of regulation of transcription and with an enrichment score of 1.59. b Cluster with an overall theme of translation/protein
biosynthesis and with an enrichment score of 0.63
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and immobilization, which induce negative protein
balance in many chronic diseases, accounted for these
findings. However, in the protein translation and bio-
synthesis clusters, more genes were up-regulated
rather than down-regulated in patients versus controls
in the present cohort. Furthermore, indicating a
minor role of inactivity in the present study, the
number of genes in muscle influenced by PMR was
small compared to findings in response to inactivity
per se [27].
Another finding that may possibly contribute to the
muscle complaints, primarily the muscle stiffness, expe-
rienced by PMR patients [28] is that proteins involved in
organizing the cytoskeleton, including tubulin delta 1
(TUBD1; similar findings with microarrays and with
qRT-PCR) and microtubule affinity-regulating kinase 4
(MARK4; similar differences in microarray and qRT-
PCR, but only significant in the former), were up-
regulated in patients before prednisolone treatment (Ta-
bles 2 and 5) [28].
Another interesting gene in this subset was the gene en-
coding brain-derived neurotrophic growth factor (BDNF).
This neurotrophic growth factor was markedly upregu-
lated in patients before treatment as determined by both
microarray and qRT-PCR (Tables 2 and 5, Fig. 5). While
BDNF traditionally is associated with diseases such as Alz-
heimer’s and mood disorders [29], studies have shown that
BDNF is also expressed in satellite cells surrounding
Fig. 5 Muscle (a) interleukin 6 (IL-6) and (b) brain-derived neurotrophic growth factor (BDNF) mRNA levels normalized to the mRNA levels of the
gene encoding ribosomal protein, large P0 (RPLP0; arbitrary units), in patients with polymyalgia rheumatica (PMR, n = 9) and non-PMR control
subjects (n = 9) before and after treatment with prednisolone (20 mg/day) for 14 days. Values are relative to untreated controls (=1.0) and shown
on a logarithmic scale. Data are geometric mean and errors bars SEM
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skeletal muscle cells, and, based on studies in rats, a role
for BDNF in maintaining the satellite cell population has
been suggested [30]. We have previously shown that PMR
is associated with high intramuscular levels of proinflam-
matory cytokines [5], and it might be speculated that in
untreated PMR, BDNF is upregulated to counter the
muscle damage resulting from the inflammatory processes
as well as the muscle degeneration resulting from the re-
duced physical activity level of PMR patients.
Finally, the transferrin receptor/CD71 (TFRC) gene
was down-regulated 3 fold in patients before treatment.
The transferrin receptor protein is involved in the trans-
port of iron into cells, it is required for erythrocyte de-
velopment, and it is associated with diseases such as
iron deficiency, anemia, and chronic disease in general.
It has been suggested that low levels of soluble transfer-
rin receptors reflect adaptation to iron deficiency and/or
inhibition of iron resorption [31]. It is conceivable that
in this group of patients, TFRC is down-regulated due to
the chronic inflammatory disease burden associated with
PMR. While intramyocellular iron deficiency may ensue,
it is not likely that the muscular down regulation of
TFRC was secondary to systemic iron deficiency. This is
so because none of the subjects exhibited anemia. Other
studies have identified that PMR is associated with anti-
bodies against ferritin [32, 33]. Taken together, this sug-
gests that iron metabolism and the function of proteins
that rely on iron-binding may be influenced in PMR.
Genes responding to prednisolone in PMR patients
The phenotype of PMR in this and other studies [1, 5,
15, 34] profoundly responds to treatment with glucocor-
ticoids, indicating that important information about the
pathophysiology of the disease can be achieved by study-
ing the gene expression before and after prednisolone
treatment. Moreover, if studying only untreated subjects,
it is conceivable that, due to sampling errors, including
unrecognized impacts of e.g. diurnal gene expression
variations between patients and controls, discovery of all
genes relevant to the pathophysiology of PMR would not
be achieved. For these reasons, comparison of expression
levels before and after symptom eliminating prednisol-
one treatment in patients was also used for the identifi-
cation of genes with importance for PMR. The number
of genes that responded to treatment in a given direction
only in patients was 131. Indicating that these genes
were, in fact, involved in the pathophysiology of PMR, of
the 131 mentioned genes that responded to treatment in
patients, only 2 also responded in controls subjects, and
they did so in the direction opposite to that seen in the
patients. Genes responding in the same direction to
prednisolone in both patients and controls were not em-
phasized, because it is likely that the response reflected a
general effect of glucocorticoids of no importance for
the pathophysiology of PMR.
The functional clusters in this subset of genes in-
cluded genes involved in the organization of the cyto-
skeleton and genes relevant for the extracellular
matrix. In this context, it is of note that both TUBD1
and MARK4 were down-regulated by prednisolone,
the fold changes being significant in microarray and
qRT-PCR, respectively (Table 5). The fact that such
genes respond to prednisolone treatment in patients
with PMR is in line with the hypothesis that muscle
stiffness may be due to abnormal expression of
cytoskeleton-related genes. Correspondingly, clinical
remission, including abolishment of muscle stiffness,
happened in parallel with or due to normalization of
expression of such genes.
Genes differentially expressed in untreated PMR patients
vs controls and also responding to prednisolone in
patients
The strongest evidence in favor of a pathogenic role of a
given gene would be that its expression differed between
untreated patients and controls, and, furthermore, chan-
ged with prednisolone treatment in the former. The
number of such genes was 44 in the present cohort.
Strongly indicating that these genes do in fact play a role
in PMR, the response to prednisolone of all but one of
the 44 genes counteracted the difference in gene expres-
sion between untreated patients and controls. In this
group of genes, the predominant biological functions ap-
peared to be regulation of transcription as well as pro-
tein translation/biosynthesis.
The finding that the expression of some genes dif-
fered between untreated patients and controls while
not responding to prednisolone treatment in patients
may indicate that clinical remission may be achieved
even though the underlying disease mechanisms are
not completely resolved or that not all differences in
gene expression may be of importance for clinical
symptoms. As a limitation of the present study, it
should be noted, however, that while all patients
achieved clinical remission during the relatively brief
14-day treatment period, some genes might respond
to long-term treatment only. Conversely, it is also in-
teresting to note that in the untreated patients, some
genes, the expression of which did not differ from
that of controls, were, nevertheless, selectively influ-
enced by prednisolone. It may be that in the patients
the processes regulated by these genes were impaired
by other, non-genetic factors that possibly also re-
sulted in increased sensitivity to prednisolone. If so,
the condition would be ameliorated by a prednisolone-
induced effect on these genes.
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Conclusions
This study is the first to demonstrate changes in the
gene expression in skeletal muscle in PMR. The study
has identified a number of genes that may play a role in
the pathophysiology of PMR. Moreover, we show that
the expression of the IL6 gene is upregulated in muscle
in PMR, a finding that adds to the substantial body of
evidence that this cytokine is central to the disease.
Follow-up studies are needed to elucidate the exact
pathophysiological relevance of the identified genes;
however, it appears that many of the genes are involved
in the regulation of protein biosynthesis, which may
suggest that abnormal protein metabolism is a disease
mechanism in PMR. Effects of prednisolone on genes in-
volved in the organization of the cytoskeleton and the
intracellular matrix in PMR patients may contribute to
the amelioration, seen in response to treatment, of the
muscle stiffness.
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